A comprehensive gene–environment interaction analysis in Ovarian Cancer using genome‐wide significant common variants

As a follow‐up to genome‐wide association analysis of common variants associated with ovarian carcinoma (cancer), our study considers seven well‐known ovarian cancer risk factors and their interactions with 28 genome‐wide significant common genetic variants. The interaction analyses were based on data from 9971 ovarian cancer cases and 15,566 controls from 17 case–control studies. Likelihood ratio and Wald tests for multiplicative interaction and for relative excess risk due to additive interaction were used. The top multiplicative interaction was noted between oral contraceptive pill (OCP) use (ever vs. never) and rs13255292 (p value = 3.48 × 10−4). Among women with the TT genotype for this variant, the odds ratio for OCP use was 0.53 (95% CI = 0.46–0.60) compared to 0.71 (95%CI = 0.66–0.77) for women with the CC genotype. When stratified by duration of OCP use, women with 1–5 years of OCP use exhibited differential protective benefit across genotypes. However, no interaction on either the multiplicative or additive scale was found to be statistically significant after multiple testing correction. The results suggest that OCP use may offer increased benefit for women who are carriers of the T allele in rs13255292. On the other hand, for women carrying the C allele in this variant, longer (5+ years) use of OCP may reduce the impact of carrying the risk allele of this SNP. Replication of this finding is needed. The study presents a comprehensive analytic framework for conducting gene–environment analysis in ovarian cancer.

[1]  A. Whittemore,et al.  Multiple regions within 8q24 independently affect risk for prostate cancer , 2007, Nature Genetics.

[2]  Harvey Risch,et al.  Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence , 2018, American journal of epidemiology.

[3]  W. Willett,et al.  Interactions Between Genome-Wide Significant Genetic Variants and Circulating Concentrations of 25-Hydroxyvitamin D in Relation to Prostate Cancer Risk in the National Cancer Institute BPC3 , 2017, American journal of epidemiology.

[4]  Harvey Risch,et al.  Combined and interactive effects of environmental and GWAS-identified risk factors in ovarian cancer. , 2013, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[5]  Yurii B. Shvetsov,et al.  Genome-wide significant risk associations for mucinous ovarian carcinoma , 2015, Nature Genetics.

[6]  A. Whittemore,et al.  Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies. , 2013, International journal of epidemiology.

[7]  Myles Brown,et al.  Molecular Determinants for the Tissue Specificity of SERMs , 2002, Science.

[8]  A. Whittemore,et al.  Common variants at 19p13 are associated with susceptibility to ovarian cancer , 2010, Nature Genetics.

[9]  A. Whittemore,et al.  A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24 , 2010, Nature Genetics.

[10]  S. Kjær,et al.  Tubal ligation and salpingectomy and the risk of epithelial ovarian cancer and borderline ovarian tumors: a nationwide case–control study , 2015, Acta obstetricia et gynecologica Scandinavica.

[11]  M. Pike,et al.  Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. , 2014, Journal of the National Cancer Institute.

[12]  Nilanjan Chatterjee,et al.  Likelihood ratio test for detecting gene (G)-environment (E) interactions under an additive risk model exploiting G-E independence for case-control data. , 2012, American journal of epidemiology.

[13]  V. Beral,et al.  Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. , 2015, Lancet.

[14]  S. Shim,et al.  Bilateral salpingectomy can reduce the risk of ovarian cancer in the general population: A meta-analysis. , 2016, European journal of cancer.

[15]  Sebastian M. Armasu,et al.  Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer , 2013, Nature Communications.

[16]  Bhramar Mukherjee,et al.  Current Challenges and New Opportunities for Gene-Environment Interaction Studies of Complex Diseases. , 2017, American journal of epidemiology.

[17]  A. Weaver,et al.  Effect of tubal sterilization technique on risk of serous epithelial ovarian and primary peritoneal carcinoma. , 2014, Gynecologic oncology.

[18]  Wei Lu,et al.  Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer , 2013, Nature Genetics.

[19]  M. Pike,et al.  A splicing variant of TERT identified by GWAS interacts with menopausal estrogen therapy in risk of ovarian cancer , 2016, International journal of cancer.

[20]  Kconfab Investigators,et al.  Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer , 2017 .

[21]  T J VanderWeele,et al.  Sample Size and Power Calculations for Additive Interactions , 2012, Epidemiologic methods.

[22]  M. Pike,et al.  Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium. , 2013, Endocrine-related cancer.

[23]  V. Beral,et al.  Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies , 2015, The Lancet.

[24]  R. Sankila,et al.  Cancer incidence in the first-degree relatives of ovarian cancer patients. , 1996, British Journal of Cancer.

[25]  A. Whittemore,et al.  A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2 , 2009, Nature Genetics.

[26]  M. Pike,et al.  Population Distribution of Lifetime Risk of Ovarian Cancer in the United States , 2015, Cancer Epidemiology, Biomarkers & Prevention.

[27]  A. Whittemore,et al.  Assessment of Multifactor Gene–Environment Interactions and Ovarian Cancer Risk: Candidate Genes, Obesity, and Hormone-Related Risk Factors , 2016, Cancer Epidemiology, Biomarkers & Prevention.

[28]  D. Oram,et al.  Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial , 2016, The Lancet.

[29]  D. Easton,et al.  A systematic review and meta‐analysis of family history and risk of ovarian cancer , 1998, British journal of obstetrics and gynaecology.

[30]  A. Berchuck,et al.  Role of common genetic variants in ovarian cancer susceptibility and outcome: progress to date from the ovarian cancer association consortium (OCAC) , 2012, Journal of internal medicine.

[31]  H. Grönberg,et al.  Ovarian cancer risk after salpingectomy: a nationwide population-based study. , 2015, Journal of the National Cancer Institute.

[32]  Kconfab Investigators,et al.  Identification of six new susceptibility loci for invasive epithelial ovarian cancer , 2015 .

[33]  S. Vansteelandt,et al.  American Journal of Epidemiology Practice of Epidemiology a Weighting Approach to Causal Effects and Additive Interaction in Case-control Studies: Marginal Structural Linear Odds Models Discussion and Implications for Model Specification Table 1. Results for Simulation Comparing Marginal Structural , 2022 .

[34]  Brooke L. Fridley,et al.  GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer , 2013, Nature Genetics.

[35]  M. Pike,et al.  Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case–control studies , 2012, The Lancet. Oncology.

[36]  M. Pike,et al.  Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin , 2009, Cancer.

[37]  Lara E Sucheston-Campbell,et al.  Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer , 2017, Nature Genetics.

[38]  Nilanjan Chatterjee,et al.  Common genetic polymorphisms modify the effect of smoking on absolute risk of bladder cancer. , 2013, Cancer research.

[39]  Patrick Neven,et al.  Evidence of Gene–Environment Interactions between Common Breast Cancer Susceptibility Loci and Established Environmental Risk Factors , 2013, PLoS genetics.

[40]  P. Brown,et al.  Estrogen induces c-myc gene expression via an upstream enhancer activated by the estrogen receptor and the AP-1 transcription factor. , 2011, Molecular endocrinology.

[41]  Peter Kraft,et al.  Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. , 2016, Cancer discovery.

[42]  Roderick J. A. Little,et al.  Statistical Analysis with Missing Data: Little/Statistical Analysis with Missing Data , 2002 .

[43]  Tyler J. VanderWeele,et al.  Estimating measures of interaction on an additive scale for preventive exposures , 2011, European Journal of Epidemiology.

[44]  M. Pike,et al.  Association Between Menopausal Estrogen-Only Therapy and Ovarian Carcinoma Risk , 2016, Obstetrics and gynecology.

[45]  A. Whittemore,et al.  Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31 , 2013, Nature Communications.

[46]  S. Cross,et al.  Fine‐scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer , 2016, International journal of cancer.

[47]  A. Bagchi,et al.  The PVT1-MYC duet in cancer , 2015, Molecular & cellular oncology.

[48]  Nilanjan Chatterjee,et al.  Analysis of Case–Control Studies in Genetic Epidemiology , 2007 .